Press Releases

Date Title  
Toggle Summary Audentes Therapeutics To Present At The Leerink Partners Rare Disease Roundtable
SAN FRANCISCO, CA – September 24, 2014 – Audentes Therapeutics, Inc., a private biotechnology company dedicated to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced that Matthew Patterson, President and Chief Executive Officer,
Toggle Summary Audentes Therapeutics Announces Six Abstracts To Be Presented At The American Society Of Gene And Cell Therapy Meeting May 21-24, 2014
Data to be presented demonstrate continued encouraging results from preclinical studies of AT001 for the treatment of X-Linked Myotubular Myopathy SAN FRANCISCO – May 19, 2014   – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene
Toggle Summary Audentes Therapeutics Announces Significant Additions To Leadership Team
Dr. Suyash Prasad joins as Senior Vice President and Chief Medical Officer SAN FRANCISCO, CA – March 4, 2014   – Audentes Therapeutics, Inc., a biotechnology company dedicated to the development and commercialization of innovative treatments for rare diseases using gene therapy technology, has
Toggle Summary Audentes Therapeutics And Genethon Announce Agreement To Develop Treatment For Severe Genetic Disease X-linked Myotubular Myopathy
Promising preclinical data recently published in Science Translational Medicine SAN FRANCISCO, CA – February 5, 2014 – Audentes Therapeutics, Inc., a biotechnology company dedicated to the development of innovative treatments for rare muscle diseases, and Genethon, a non-profit organization
Toggle Summary REGENX BIOSCIENCES AND AUDENTES THERAPEUTICS ENTER INTO EXCLUSIVE LICENSE AGREEMENT FOR DEVELOPMENT OF TREATMENTS FOR SERIOUS, RARE MUSCLE DISEASES USING NAV™ VECTORS
WASHINGTON & SAN FRANCISCO – July 30, 2013 – REGENX Biosciences, LLC and Audentes Therapeutics, Inc. announce that they have entered into an agreement for the development and commercialization of products to treat X-Linked Myotubular Myopathy (XLMTM) and Pompe disease
Toggle Summary AUDENTES THERAPEUTICS RAISES $30 MILLION IN SERIES A FINANCING
Funding creates premier global biotechnology company dedicated to the development of treatments for rare muscle diseases using gene therapy technology SAN FRANCISCO, CA. – July 18, 2013   – Audentes Therapeutics Inc., a recently founded biotechnology company dedicated to the development of